Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Ma L, Zhao Z, Racine-Brzostek SE, Yang HS. A rare case of persistent pseudohypobicarbonatemia arising from chemistry analyzer-specific interference. Clin Chim Acta. 2021;519:308-310.

Matrai CE, Ohara K, Eng KW, Glynn SM, Chandra P, Chatterjee-Paer S, et al. Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence. Int J Gynecol Pathol. 2021.

Rendeiro AF, Vorkas CK, Krumsiek J, Singh HK, Kapadia SN, Cappelli LV, et al. Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment. Front Immunol. 2021;12:809937.

Crane GM, Liu Y-, Chadburn A. Spleen: Development, anatomy and reactive lymphoid proliferations. Semin Diagn Pathol. 2021;38(2):112-124.

Hissong E, Chiu K, Park H, Solomon J, Song W, Jessurun J. Thyroid-Like Cholangiocarcinoma: Histopathological, Immunohistochemical, In-Situ Hybridization and Molecular Studies on an Uncommon Emerging Entity. Int J Surg Pathol. 2021:10668969211013906.

Tameni A, Sauta E, Mularoni V, Torricelli F, Manzotti G, Inghirami G, et al. The DNA-helicase HELLS drives ALK ALCL proliferation by the transcriptional control of a cytokinesis-related program. Cell Death Dis. 2021;12(1):130.

Yantiss RK, Qin L, He B, Crawford CV, Seshan S, Patel S, et al. Intestinal Abnormalities in Patients With SARS-CoV-2 Infection: Histopathologic Changes Reflect Mechanisms of Disease. Am J Surg Pathol. 2021.

Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, et al. G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer. Nat Commun. 2021;12(1):6662.

Wang Y, Yan F, Nasar A, Chen Z-, Altorki NK, Stiles B, et al. CUL4 Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival. Am J Pathol. 2021;191(9):1638-1650.

Francini E, Montagnani F, Nuzzo PV, Gonzalez-Velez M, Alimohamed NS, Rosellini P, et al. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. JAMA Netw Open. 2021;4(7):e2116536.